pharma · Myelofibrosis · Myelodysplastic syndromes (MDS)
Geron Netherlands B.V.
Geron Netherlands drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Geron Netherlands drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L01) compound in Geron Netherlands's portfolio. Molecular target: Telomerase reverse transcriptase.
Development asset linked to Geron Netherlands in public FDA and regional records.